Viridian Therapeutics, Inc.\DE (VRDN) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Q3 2025 value amounting to -$22.96.
- Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) rose 6107.81% to -$22.96 in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.13, marking a year-over-year increase of 5031.34%. This contributed to the annual value of -$3.98 for FY2024, which is 2513.87% up from last year.
- As of Q3 2025, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) stood at -$22.96, which was up 6107.81% from -$66.99 recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) registered a high of -$0.86 during Q3 2022, and its lowest value of -$178.15 during Q4 2022.
- For the 5-year period, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) averaged around -$26.02, with its median value being -$2.21 (2021).
- In the last 5 years, Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) tumbled by 723544.72% in 2022 and then surged by 9916.14% in 2023.
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) stood at -$2.43 in 2021, then crashed by 7235.45% to -$178.15 in 2022, then skyrocketed by 99.16% to -$1.49 in 2023, then rose by 21.33% to -$1.18 in 2024, then tumbled by 1853.62% to -$22.96 in 2025.
- Its last three reported values are -$22.96 in Q3 2025, -$66.99 for Q2 2025, and -$57.94 during Q1 2025.